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Abbreviation Full Term 
A30 Maximal lysis 
ANOVA Analysis of variance 
CI Clotting index 
ELISA Enzyme-linked immunosorbent assay 
FFP Fresh frozen plasma 
FVIII Factor VIII 
LIA Line immunoassay 
MA Maximal strength amplitude 
MRTG Maximal rate of thrombus generation 
NHLBI National Heart, Lung, and Blood Institute 
PT Prothrombin time 
PTT Partial thromboplastin time 
R-time Reaction time 
ROTEM Rotational thromboelastography 
TEG Thromboelastography 
TF Tissue factor 
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TMRTG Time to maximal rate of thrombus generation 
VWD Von Willebrand Disease 
VWF Von Willebrand Factor 
VWF:Ag Von Willebrand Factor Antigen 
VWF:RCo Von Willebrand Factor Activity 
 36 
 37 
Abstract 38 
Von Willebrand Disease (VWD) is an inherited bleeding disorder that is caused by a 39 
quantitative or qualitative deficiency of Von Willebrand Factor (VWF).  The National Heart, Lung, and 40 
Blood Institute (NHLBI) guidelines for the diagnosis of VWD state that an VWF Activity (VWF:RCo) of 41 
<30 IU/dL or <50 IU/dL with symptoms of clinical bleeding are consistent with the diagnosis of VWD.  42 
However, current gold standard diagnostic testing takes days to have complete results.  43 
Thromboelastography (TEG) is a testing method that provides a graphical trace that represents the 44 
viscoelastic changes seen with fibrin polymerization in whole blood, therefore providing information 45 
on all phases of the coagulation process.  This study describes the TEG characteristics in 160 patients 46 
who presented for workup of a bleeding disorder and a subset of those were subsequently 47 
diagnosed with VWD.  The TEG parameters, K-time (representing the dynamics of clot formation) 48 
and the maximal rate of thrombus generation (MRTG), was found to be sensitive in detecting 49 
patients with VWF:RCo <30 IU/dL.  The TEG unlike VWF:RCo can be done in real time and results are 50 
available to the clinician within an hour.  This will definitely be beneficial in acute situations like 51 
evaluation of and management of acute bleeding in patients with acquired deficiencies of VWF and 52 
may play an important role in the surgical management of patients with VWD. 53 
 54 
Introduction 55 
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Von Willebrand Disease (VWD) is an inherited disorder associated with clinical bleeding 56 
abnormalities.  Many subtypes exist based on quantitative or qualitative defects in Von Willebrand 57 
Factor (VWF).  The gold standard diagnostic testing at the time of the study included:  VWF Activity 58 
(VWF:RCo), VWF Antigen (VWF:Ag) and Factor VIII (FVIII) Activity1; newer assays such as the Collagen 59 
binding and GP1bM are relatively new and were not available at the time this study was conducted.  60 
Patients with VWD may have a prolonged partial thromboplastin time (PTT) and decreased levels of 61 
FVIII activity secondary to increased clearance of FVIII because the protein is no longer protected by 62 
the FVIII – VWF circulating protein complex. According to the National Heart, Lung, and Blood 63 
Institute (NHLBI) guidelines, those with the diagnosis of VWD have VWF:Ag levels <50 IU/dL and 64 
VWF:RCo levels <50 IU/dL and variable levels of FVIII activity compared to normal laboratory 65 
reference ranges.1  66 
There are many difficulties associated with current diagnostic methods (such as different 67 
methodologies available for laboratory tests, enzyme-linked immunosorbent assay (ELISA) vs. line 68 
immunoassay (LIA); and a high coefficient of variation with each of these tests) and the inability to 69 
measure physiologic function. 70 
TEG is a testing method that provides a graphical trace that represents the viscoelastic 71 
changes seen with fibrin polymerization in whole blood, therefore providing information on all 72 
phases of the coagulation process.2–4  Since it is a global assay that evaluates clot formation from 73 
initiation to fibrinolysis it has the ability to potentially pin point abnormalities in any step along the 74 
process.   75 
The TEG can be done in real time, unlike the VWF:Ag and VWF:RCo.  The standard TEG assay 76 
has not been thought to be of use in VWD because of the lack of shear stress, which is essential for 77 
the activation of VWF.  The aims of this study were to evaluate the parameters of Tissue factor (TF) 78 
initiated TEG in pediatric patients with VWD, to determine if this assay is sensitive to 79 
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dysfunctional/low levels of VWF, as this does not require any significant change in procedure other 80 
than the use of TF as the activator instead of Kaolin. 81 
 82 
Materials and methods 83 
At Children’s Hospital of Michigan, all patients who present for workup of a bleeding 84 
disorder have TEG and VWD studies as part of the initial evaluation and this data was obtained from 85 
the patient medical records.  Those patients with a diagnosis of VWD had confirmatory VWF 86 
multimer analysis completed, and were further classified based on their specific VWD type.  D1472H, 87 
VWF:Gp1bm, and collagen binding testing were not widely available at the time of study, and thus 88 
were not completed.  All other patients were not identified to have any underlying bleeding 89 
disorder. 90 
A retrospective chart review of patients who presented for a bleeding disorder workup that 91 
had TF initiated TEG analysis and Von Willebrand studies completed between January 2007 and 92 
December 2015 was performed at Children’s Hospital of Michigan.  IRB approval was obtained, and 93 
current diagnostic tests for Von Willebrand Disease (CBC with platelet count, VWF:RCo and VWF:Ag, 94 
FVIII, ABO blood type; PT, PTT, Fibrinogen) and TF initiated TEG parameters, including K-time and 95 
MRTG, were compared.  Patient demographics including age, gender, and ethnic background were 96 
also reviewed. 97 
 98 
TEG Analysis 99 
In all subjects, the dynamics of blood clot formation was recorded by the TEG® 5000 100 
(Version 4.2) using the following method.  Each sample was allowed to rest for 30 minutes as 101 
recommended by Sorensen et al 3 following which the thromboelastographic analysis was 102 
  
 
This article is protected by copyright. All rights reserved. 
 
performed.  To perform the TEG analysis, 20L of 1:10,000 dilution of recombinant human tissue 103 
factor (Innovin, Dade Behring) and 20 µL of CaCl2 were added to the TEG cup, followed by 340 µL 104 
whole blood.  All samples were run for 90 minutes. 105 
The TEG analysis has five parameters.  The first parameter is the R-time, which is the period 106 
from initiation of the test until the clot initiated reaches 2mm amplitude and represents time to 107 
fibrin initiation.  The K-time refers to the time it takes the amplitude of the curve to go from 2mm to 108 
20mm and represents the dynamics of clot formation.  The third parameter is the  Angle, which is 109 
the slope between R and K; which represents the rate of clot formation.  The fourth parameter is the 110 
MA, which measures the strength of the clot formed.  Finally, A30 is the difference between MA and 111 
the amplitude of the curve after 30 minutes.2,3,5,6  112 
MRTG and TMRTG:  A Velocity Curve, as noted above, creates a graph relating clot strength 113 
over time, which correlates with the rate and amount of clot formation or fibrinogen 114 
polymerization.7 115 
 116 
Von Willebrand Studies 117 
VWF:Ag was analyzed by the STA-Liatest VWF kit (Diagnostica Stago Inc, Parsippany, NJ, 118 
USA) which is an immunoturbidimetric method that uses microlatex particles coated with rabbit 119 
anti-human vWF, and measures the absorbance as the particles agglutinate in proportion to the 120 
antigen level present. 121 
VWF:RCo is determined by a turbidimetric method that measures the change in optical 122 
density based on the sample’s von Willebrand Factor which initiates aggregation of the platelet 123 
reagent in the presence of ristocetin (BC von Willebrand Reagent – Siemens Healthcare Diagnostics 124 
Inc. Newark, DE, USA). 125 
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 126 
Fibrinogen 127 
Quantitative determination of fibrinogen in plasma was performed by the Clauss clotting 128 
method.  The fibrinogen quantitation and clotting factor assays were performed on the STA-R 129 
Evolution® (Diagnostica Stago, Inc, Parsippany, NJ, USA), at the Special Coagulation Laboratory at 130 
Children’s Hospital of Michigan. 131 
 132 
Blood Counts 133 
CBCs results were obtained as a part of the routine clinical work up for the patient.  134 
 135 
Coagulation Factor Assays 136 
The one-stage PTT based clotting assay was used to determine FVIII activity and was 137 
performed on the STA-R Evolution (Diagnostica Stago, Inc, Parsippany, NJ, USA) using kaolin PTT 138 
reagent (CK Prest – Diagnostica Stago, Inc, Parsippany, NJ, USA) and George King Biomedical 139 
congenital FVIII deficient plasma (Overland Park, KS, USA). 140 
 141 
Statistical Analysis 142 
Comparison data by VWD Types, VWD percentage groups and controls are reported using 143 
means and standard deviations.  Mean differences between groups were conducted using a 144 
parametric analysis of variance procedure (ANOVA), with a Tukey test to balance Type 1 error and 145 
power. If assumptions of homogeneity of variance were violated a non-parametric Kruskal Wallis 146 
test would be substituted, followed by pair-wise comparisons using a non-parametric Mann Whitney 147 
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U test. An independent receiver operating characteristic curve (ROC) was performed to compare K-148 
time on TEG to VWF:RCo in patients with VWF:RCo <30 IU/dL. A curvilinear procedure was 149 
performed to examine best fit for changes in MRTG related to changes in K-time. Statistical 150 
significance was considered achieved at a p-value <0.05, two-tailed. All statistical procedures were 151 
performed using SPSS Version 25.0 IBM Inc. Chicago, Ill.  152 
 153 
Results 154 
A total of 160 patients (ages ranging 2 weeks to 18 years) who had a workup for a bleeding 155 
disorder that included Von Willebrand studies and TEG were included in the study.  Patient 156 
demographics, including age, sex, race, and presenting symptoms were compared, and showed no 157 
significant difference in patients with diagnosis of VWD compared to control patients.  Patient 158 
demographics based on VWF:RCo levels are presented in Supplemental Table S1.  As previously 159 
described, we did see a significantly higher FVIII activity in patients of African American ethnicity in 160 
both our control patients and VWD patients.8  Our control group consisted of 82 patients (34 males 161 
and 48 females) with the majority of patients being of Caucasian (43%) and African American (22%) 162 
descent.  Males most commonly presented with epistaxis (41%) and bruising (26%), and females 163 
with menorrhagia (25%), epistaxis (21%), and bruising (19%).  None of the female patients were on 164 
hormonal therapy at the time of diagnostic workup. 165 
Seventy-eight patients were diagnosed with VWD based on laboratory evaluation and 166 
presence of bleeding symptoms.  There were 36 males and 42 females, who were further 167 
categorized into Type 1 VWD (67 patients) and Type 2A VWD (11 patients).  The most prominent 168 
ethnicity was Caucasian (58%) followed by African American (19%), Hispanic (12%), and Other (11%).  169 
There were no patients diagnosed with Type 2B, 2N, 2M, 3, or platelet type VWD.  170 
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There were no significant differences in the clinical presentation of patients with Type 1 171 
VWD vs. Type 2A VWD.  Presenting symptoms in patients aged 10 and under (N=41; 23 males, 18 172 
females) and those aged 11 and older (N=37; 13 males, 24 females) were compared.  The most 173 
common presenting symptom in male patients was epistaxis (51%) regardless of age.  However, in 174 
female patients, the age of presentation impacted their presenting bleeding symptoms.  Those 175 
females less than 10 years of age presented most frequently with epistaxis (44%); and in patients 176 
aged 11 years and older the most frequent symptoms were epistaxis (27%) and menorrhagia (27%).  177 
The general laboratory characteristics as well as the TEG data showed no significant differences 178 
between Type 1 and Type 2A VWD patients (Supplemental Tables S2 and S3).  TEG data was 179 
reported in medians due to one outlier in the Type 2A VWD group which skewed the means and did 180 
not represent overall finding in Type 2A VWD patients. 181 
Of the 160 patients evaluated in this study, 85/160 patients had VWF:RCo >50 IU/dL, 14/85 182 
of these patients were diagnosed with VWD due to significant bleeding symptoms and had levels 183 
between 50-60 IU/dL (normal range for VWF:RCo is 60 IU/dL to 120 IU/dL).   There were 45/160 184 
patients with VWF:RCo 30-50 IU/dL, 34/45 of these patients were diagnosed with VWD and 11/45 185 
were not diagnosed with any bleeding disorder. Of the 11 patients not diagnosed as a bleeding 186 
disorder, 9/11 were blood group O and 2/11 were blood group A and had normal levels on repeat 187 
testing.  There were 30/160 patients with VWF:RCo <30 IU/dL and all were diagnosed with VWD.  All 188 
75 patients with VWF:RCo <50 IU/dL, were divided into 2 groups based on VWF:RCo levels: 30-50 189 
IU/dL and <30 IU/dL.  The TEG parameter, K-time, (time for increase in amplitude from 2mm to 190 
20mm representing the dynamics of clot formation, normal <2.2 minutes) was determined abnormal 191 
for values ≥2.2 minutes.  An example of a normal TEG in a healthy control in comparison to those 192 
patients with VWD with varying VWF:RCo is reflected in Figure 1. 193 
The lab characteristics of these patients are presented, including FVIII, platelet count, and 194 
fibrinogen levels (Supplemental Table S4).  Those patients with VWF:RCo <30 IU/dL had significantly 195 
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longer K-times than those with VWF:RCo >50 IU/dL.  PTT assays on 4 patients with VWF:RCo <50 196 
IU/dL and 3 patients with VWF:RCo >50 IU/dL were not available, and are not included in the means. 197 
Of the patients with VWF:RCo <30 IU/dL, 23/30 (77%) had an abnormal K-time of  ≥2.2 198 
minutes (p-value of ≤0.001); whereas patients with low VWF:RCo 30-50 IU/dL, only 13/45 (29%) had 199 
an abnormal K-time of ≥2.2 minutes, which was not statistically significant.  Regression analysis of K-200 
time and MRTG in comparison to VWF:RCo shows that for every 1 IU/dL decrease in VWF:RCo there 201 
is an equal increase in both K-time and MRTG levels (Table 1).  A ROC curve for patients with 202 
VWF:RCo <30 IU/dL and abnormal K-time showed an area under the curve of 0.67 (p-value = 0.003) 203 
(Figure 2).  An analysis of the MRTG showed a mean of 9.45 in patients with VWF:RCo <30 IU/dL, a 204 
mean of 10.9 in patients with VWF:RCo 30-50 IU/dL, and a mean of 11.26 in patients with normal 205 
VWF:RCo.  There was a strong correlation (0.86) seen between patients with abnormal K-time and 206 
MRTG.  When analyzing regression data, the regression accounts for 74% (linear) and 84% 207 
(exponential/logistic) of the explained variance in abnormal K-time (Figure 3).  There was a 208 
moderate correlation (0.34) seen between patients with abnormal K-time and FVIII, however, when 209 
analyzing regression data the correlation only accounts for 11% of the explained variance in 210 
abnormal K-time values.  Patients with abnormal K-time and abnormal fibrinogen levels and platelet 211 
counts were also compared, and showed no significant correlation, indicating that these were not 212 
the determinants that influenced the K-time. 213 
In patients diagnosed with VWD, 32 patients had previously qualified for a DDAVP trial and 214 
VWF:Ag, VWF:RCo, and TEG parameters were compared at 1 hour, 2 hours, and 4 hours post 215 
treatment with DDAVP.  There were 13 males and 19 females, with a mean age of 10.91 years.  Of 216 
the 32 patients who underwent a DDAVP trial, 29/32 patients had normalization of VWF:RCo at 1 217 
hour post DDAVP, and 25/32 patients had normalization of K-time at 1 hour post DDAVP treatment.  218 
There were 3/32 patients that were found to be non-responders to DDAVP treatment in regard to 219 
serial VWF:RCo levels at 1 hour, 2 hours, and 4 hours post DDAVP, however 2/3 of the patients did 220 
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have normalization of their K-times.  In reviewing K-time normalization, 2/7 patients who were 221 
abnormal at 1 hour post DDAVP had normalization at 2 hours post DDAVP, suggesting that some 222 
patients may be slow responders to treatment.  Mean MRTG of patients was compared before and 223 
after administration of DDAVP using the test of spherity within subject effects, and was found to be 224 
significant, p-value ≤0.001 in all paired samples test (Table 2). 225 
Eleven patients in our study have now had the collagen binding assay completed to 226 
compliment their diagnostic evaluations.  These results were compared with their TEG parameters 227 
and VWF:Ag and VWF:RCo levels.  We did not find any correlation when comparing this assay to 228 
these parameters; however this may be the result of the extremely small sample size. 229 
 230 
Discussion 231 
VWD is the most common bleeding disorder, and has been estimated to have an prevalence 232 
of up to 1.3%, and affecting males and females equally.9,10  Typically, patients present with skin and 233 
mucosal bleeding, including easy bruising, epistaxis, bleeding from the gums, and heavy menstrual 234 
bleeding.  Management of acute bleeding episodes in these patients primarily consists of 235 
replacement of the deficient coagulation protein.  Treatment is often empiric as monitoring of the 236 
VWF levels in real time is often not possible in most clinical centers.  Significant bleeding is often 237 
associated with VWF:RCo levels <30 IU/dL, although patients with levels between 30-50 IU/dL are 238 
also described to have bleeding symptomatology. 239 
In many situations, prothrombin time (PT) and PTT may be sufficient for monitoring patients 240 
with coagulation disorders and their response to medications, including those with VWD but these 241 
tests are neither specific nor sensitive.  In critically ill patients or those with acute bleeding it is 242 
imperative that quick and reliable information be available to assist in physician decision-making.  243 
The aim of our study was to evaluate the use of TF- activated TEG and its role in diagnosing VWD.  244 
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We were able to show that patients with VWF <30 IU/dL had significant changes of the TEG 245 
parameters:  k-time, MRTG, and TMRTG.  With this knowledge, it may be beneficial to clinicians to 246 
use TEG as one of the monitoring tools in patients with this diagnosis. 247 
The lack of shear stress in the TEG assay was thought to make it insensitive to VWF activity.  248 
A recent prospective study aimed to differentiate adult patients with VWD from healthy controls 249 
using TEG and rotational thromboelastography (ROTEM)11 and were able to find differences in R-250 
time and the clotting index (CI) in those with VWD using TEG, however no differences were seen 251 
using ROTEM.  Modified TEG using Ristocetin activation has been found to be useful in the diagnosis 252 
of VWD.  To date, there have not been any published studies looking at TEG and VWD in children 253 
and also no studies that have looked at using a tissue factor activator in patients with VWD. 254 
VWF is an important component of fibrinogen polymerization. Previously, it has been shown 255 
that fibrinogen binding to the glycoprotein IIb-IIIa complex induces platelet aggregation under low 256 
shear stress environments, and the aggregates formed under these conditions are unstable, making 257 
the effects reversible.  In high shear stress conditions, von Willebrand factor interacts with both 258 
platelet binding sites, glycoprotein IIb-IIIa and glycoprotein Ib-IX to induce platelet aggregation 259 
without the influence of fibrinogen.12  Although no published data exists, we hypothesize the 260 
prolonged K-time seen in patients with VWD despite normal fibrinogen levels may be due to their 261 
low levels of VWD:Ag and/or VWD:RCo which in turn, interferes with the clot kinetics in these 262 
patients. 263 
Our study shows that the TF-activated TEG demonstrates impaired clot formation in patients 264 
with VWF:RCo <30 IU/dL as reflected by the prolongation in the K-time and the low MRTG and can 265 
be helpful in identifying those patients with VWF:RCo levels in this range who are at higher risk of 266 
major bleeding. This is of benefit in non-life threatening acute bleeding (e.g. epistaxis) where often 267 
replacement therapy is still empiric as results of the evaluation often may take several hours to days.  268 
It also reflects response to DDAVP treatment as reflected by the correction in K-time and MRTG. This 269 
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can be extremely helpful in preparation for surgery, where post DDAVP levels are often not available 270 
prior to surgery and correction is assumed based on previous testing results.  Since fibrinogen is a 271 
major determinant of the K time, when patients present with acute bleeding and have normal 272 
fibrinogen activity/levels, but abnormal K time on TF activated TEG, substitution with VWF 273 
containing factor products would be consideration instead of non-specific substitution with fresh 274 
frozen plasma (FFP). 275 
The TEG, unlike VWF:RCo, can be done in real time and results are available to the clinician 276 
within an hour. It may also help physicians monitor response to treatment, frequency of treatment, 277 
and the need for prophylactic dosing in patients with VWD undergoing surgical interventions or 278 
those at high risk for bleeding episodes.  Therefore, obtaining a baseline TF-initiated TEG evaluation 279 
in patients with VWD may be of benefit for diagnosis as well as monitoring of therapy. 280 
Given that our study is retrospective, newer diagnostic tests were unable to be completed, 281 
including D1472H heterozygote testing for those with low VWF levels and collagen binding assays for 282 
those with Type 2 disease.  In addition, we were unable to access bleeding scores in patients prior to 283 
2012 and thus we could not analyze this data to see if those with higher scores had a higher 284 
likelihood of derangements in their TEG.   285 
The next step will be to evaluate if this difference is also seen with Kaolin, which is the 286 
standard TEG assay.  Kaolin activates the intrinsic coagulation pathway in addition to activating 287 
platelets by releasing platelet factor 3, and thus may allow for normalization of the TEG despite 288 
deficient von Willebrand factor leading to lack of sensitivity.13,14  We anticipate that Kaolin being a 289 
stronger agonist may make the test less sensitive to VWF related changes on TEG (K-time) and 290 
Velocity curve (MRTG). 291 
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FIGURE 1 Sample TEG graphical trace comparing K-time with varying VWF:RCo levels 349 
FIGURE 2 ROC Curve comparing K-time on TEG to VWF:RCo in patients with VWF:RCo < 30 IU/dL; 350 
R2 = 0.067, p-value = 0.003 351 
FIGURE 3 A. Linear curve fit for changes in MRTG related to changes in K-time, R2 = 0.74, p-value 352 
≤0.001; and B. Exponential/logistic curve fit for changes in MRTG related to changes in K-time, 353 
R2 = 0.84, p-value ≤0.001 354 
 355 
TABLE 1 Regression for method comparison against the reference method, VWF:RCo 356 
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Variable Intercept 95% CI Slope 95% CI P-Value 
K-Time 2.1922 2.0149 to 
2.3694 
-1.0014 -1.0036 to 
-0.9992 
<0.0001 
MRTG 10.1912 9.2173 to 
11.1650 
-0.9907 -1.0027 to 
-0.9788 
<0.0001 
VWF:RCo: Von Willebrand Factor activity, CI: Confidence interval, MRTG: Maximal rate of thrombin 357 
generation 358 
 359 
TABLE 2 Mean MRTG and K-time values in patients with diagnosis of VWD who participated in 360 
DDAVP trial 361 
 Pre-DDAVP 
(N = 32) 
1 Hour Post-
DDAVP 
(N = 32) 
2 Hours Post-
DDAVP 
(N = 32) 
4 Hours Post-
DDAVP 
(N = 31) 
Mean MRTG 9.91* 12.34 12.9 12.6 
Mean K-time 2.17 1.75 1.65 1.71 
MRTG: Maximal rate of thrombin generation, VWD: Von Willebrand Disease 362 
*p-value ≤0.001 363 
 364 
 365 
 366 
 367 
 368 
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